Advertisement

Picture Swiss Biotech Association LSE Global Village 2025 Basel 650x100px
Organisation › Details

Silence Therapeutics (Group)

Silence Therapeutics plc (AIM: SLN) is a leading global biotechnology company dedicated to the discovery, development and delivery of targeted, systemic RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses multiple proprietary short interfering RNA (siRNA) delivery technology platforms including AtuPLEX™, a system that enables the functional delivery of siRNA molecules to targeted diseased tissues and cells, while increasing their bioavailability and intracellular uptake. Additionally, the company has a platform of novel siRNA molecules, AtuRNAi, which provide a number of advantages over conventional siRNA molecules, including reduced cytokine induction and decreased manufacturing costs. Silence's unique RNAi assets also include structural features for a next generation of RNAi molecules and additional proprietary siRNA sequences against more than 50 highly valued oncology and other disease targets. The Company's lead internal drug candidate is Atu027, a liposomal AtuRNAi formulation in clinical development for systemic cancer indications and one of the most clinically advanced RNAi therapeutics in the area of oncology. Silence is currently conducting an open-label, single-centre, dose-escalation Phase I study with Atu027 in patients with advanced solid tumors involving single, as well as, repeated intravenous administration. The study is expected to be completed in the second half of 2011. The Company's RNAi therapeutic platform has received key validation through multiple partnerships with pharmaceutical companies including AstraZeneca, Dainippon Sumitomo, Pfizer, and Quark. Silence is actively pursuing the establishment of additional partnerships. *

 

Period Start 2007-04-26 renamed
  Predecessor SR Pharma (Group)
Products Industry RNAi drug (RNAi therapeutic)
  Industry 2 SLN124 (Silence Therapeutics)
Persons Person Tooman, Craig A. (Silence Therapeutics 202202– CEO joined 1/21 before Vyome Tx + Aratana Tx + Avanzar Medical + Enzon)
  Person 2 Hellums, Rhonda (Silence Therapeutics 202202– CFO joined 4/21 before KCI + Genzyme + Deer Oaks Mental Health + Aratana)
     
Region Region London, Greater London
  Country United Kingdom (GB)
  Street 72 Hammersmith Road
  City W14 8TH London
  Tel +44-20-3457-6900
    Address record changed: 2020-12-02
     
Basic data Employees D: 101 to 500 (2023-12-31)
  Currency GBP
  Annual sales 25,375,000 (revenue, consolidated (2023) 2023-12-31)
  Profit -43,267,000 (2023-12-31)
  Cash 54,031,000 (2023-12-31)
     
    * Document for »About Section«: 
     
   
Record changed: 2024-06-25

Advertisement

Picture Berlin Partner Top News Aignostics Mayo Clinic Pathology 650x200px

More documents for Silence Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture EBD Group BIO-Europe Spring 2025 Milan to 28 Feb 650x300px




» top